NCT00156013View on ClinicalTrials.gov

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Lymphoma, B-CellLymphoma, Non-Hodgkin
Interventions
DRUG

CLOFARABINE

4 mg/m\^2 days 1-5 of every cycle for a maximum of 6 cycles

Trial Locations (1)

60068

Oncology Specialists, SC, Park Ridge

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Oncology Specialists, S.C.

OTHER

NCT00156013 - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) | Biotech Hunter | Biotech Hunter